Economic Evaluation of Palivizumab in Children With Congenital Heart Disease: A Canadian Perspective

Canadian Journal of Cardiology

Volumn 27, Issue 4, 2011, Pages 523.e11-523.e15

  Harris, Kevin C ^a   Anis, Aslam H ^b   Crosby, Marsha C ^a   Cender, Laurie M ^a   Potts, James E ^a   Human, Derek G ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ARTICLE; COHORT ANALYSIS; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH ECONOMICS; HEMODYNAMICS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

EID: 80052409655     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2010.12.064     Document Type: Article

References (20)

1. Simoes E.A. Respiratory syncytial virus infection. Lancet 1999, 354:847-852.
2. Aujard Y., Fauroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir Med 2002, 96:S9-S14.
3. MacDonald N.E., Hall C.B., Suffin S.C., et al. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982, 307:397-400.
4. Moler F.W., Khan A.S., Meliones J.N., et al. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 1992, 20:1406-1413.
5. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998, 102:211-216. The American Academy of Pediatrics Committee on Infectious DiseasesCommittee on the Fetus and Newborn.
6. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997, 99:93-99. The PREVENT Study Group.
7. Groothuis J.R., Simoes E.A., Levin M.J., et al. Prophylactic administration of respiratory syncytial virum immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993, 329:1524-1530.
8. Langley J.M. Use of palivizumab in children with congenital heart disease. The Canadian Paediatric Society. Paediatr Child Health 2003, 8:631-636.
9. Feltes T.F., Cabalka A.K., Meissner H.C., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. The Cardiac Synagis Study Group. J Pediatric 2003, 143:532-540.
10. Yount L.E., Mahle W.T. Economic analysis of palivizumab in infants with congenital heart disease. Pediatr 2004, 114:1606-1611.
11. Lofland J.H., O'Connor J.P., Chatterton M.L., et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000, 22:1357-1369.
12. Nuijten M.J., Wittenberg W., Lebmeier M. Cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007, 25:55-71.
13. Reeve C.A., Whitehall J.S., Buettner P.G., et al. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. Paediatr Child Health 2006, 42:253-258.
14. Wage and salary groups in constant (2000) dollars and sex for paid workers 15 years and over for Canada, provinces, territories, census metropolitan areas and census agglomerations, 1995 and 2000. Statistics Canada Accessed March 2009. http://www12.statcan.ca/english/census01/products/standard/themes/RetrieveProductTable.cfm?Temporal=2001%26PID=56053%26APATH=3%26METH=1%26PTYPE=55440%26THEME=53%26FOCUS=0%26AID=0%26PLACENAME=0%26PROVINCE=0%26SEARCH=0%26GC=0%26GK=0%26VID=0%26VNAMEE=%26VNAMEF=%26FL=0%26RL=0%26FREE=0%26GID=431648.
15. Travel directive, appendix b: kilometric rates, effective April 1, 2008. Treasury Board of Canada Accessed March 2009. http://www.tbs-sct.gc.ca/pubs_pol/hrpubs/TBM_113/b_e.asp.
16. Shireman T.I., Braman K.S. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid's high-risk children. Arch Pediatr Adolesc Med 2002, 156:1251-1255.
17. Rawlins M.D., Culyer A.J. National Institute for Clinical Excellence and its value judgements. Br Med J 2004, 329:224-227.
18. Gafni A., Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics 2003, 21:149-157.
19. Geskey J.M., Thomas N.J., Brummel G.L. Palivizumab in congenital heart disease: should international guidelines be revised?. Expert Opin Biol Ther 2007, 7:1615-1620.
20. Kristensen K., Stensballe L.G., Bjerre J., et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009, 94:785-789.